Pirfenidone (Esbriet) May Prevent Acute Flares in IPF Patients After Lung Cancer Surgery
Treating idiopathic pulmonary fibrosis (IPF) patients with the anti-IPF drug Esbriet (pirfenidone) before and after lung surgery could be protective against acute exacerbation, or worsening of IPF, a life-threatening complication associated with lung-cancer surgery.